Treatment for angiosarcoma necessitates the collaboration of a multidisciplinary medical team that includes oncologists, surgeons, and other specialists. Surgical intervention is the primary treatment for the illness. Due to the significant risk of local relapse and distant metastatic illness, chemotherapy is also utilised. Chemotherapy and radiation therapy, on the other hand, are crucial in the treatment of Angiosarcomas both before and after surgery. Doxorubicin is the most commonly used chemotherapeutic medication to treat Angiosarcomas. However, Angiosarcomas have been successfully treated with a combination of mesna, doxorubicin, and ifosfamide. Several attempts have been made in the recent decade to create medications that target the blood vessel growth stimulant VEGF and induce angiosarcomas to shrink. Bevacizumab, irinotecan, sildenafil, SU11248, BAY43-9006, and AMG706 are among these medications. Radiation therapy involves irradiating malignancies with high-powered gamma and X-rays.
Read More: https://bloggerstrive.blogspot.com/2022/01/angiosarcomas-treatment-market-remedies.html
Click Here for Angiosarcomas treatment market Report: https://www.coherentmarketinsights.com/market-insight/angiosarcomas-treatment-market-396
